CN102219811A - Ca-4衍生物、其制法及其医药用途 - Google Patents

Ca-4衍生物、其制法及其医药用途 Download PDF

Info

Publication number
CN102219811A
CN102219811A CN2011100932765A CN201110093276A CN102219811A CN 102219811 A CN102219811 A CN 102219811A CN 2011100932765 A CN2011100932765 A CN 2011100932765A CN 201110093276 A CN201110093276 A CN 201110093276A CN 102219811 A CN102219811 A CN 102219811A
Authority
CN
China
Prior art keywords
deoxidation
methoxyl group
arh
compound
phenoxy group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011100932765A
Other languages
English (en)
Chinese (zh)
Other versions
CN102219811B (zh
Inventor
徐云根
吴梦茜
屠哲玮
司崇静
何书英
何广卫
孙丽
卞金磊
戴宇驰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hefei Medical and Pharmaceutical Co., Ltd.
China Pharmaceutical University
Original Assignee
HEFEI YIGONG MEDICINE CO Ltd
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEFEI YIGONG MEDICINE CO Ltd, China Pharmaceutical University filed Critical HEFEI YIGONG MEDICINE CO Ltd
Priority to CN 201110093276 priority Critical patent/CN102219811B/zh
Publication of CN102219811A publication Critical patent/CN102219811A/zh
Application granted granted Critical
Publication of CN102219811B publication Critical patent/CN102219811B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

CN 201110093276 2011-04-14 2011-04-14 Ca-4衍生物、其制法及其医药用途 Active CN102219811B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201110093276 CN102219811B (zh) 2011-04-14 2011-04-14 Ca-4衍生物、其制法及其医药用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201110093276 CN102219811B (zh) 2011-04-14 2011-04-14 Ca-4衍生物、其制法及其医药用途

Publications (2)

Publication Number Publication Date
CN102219811A true CN102219811A (zh) 2011-10-19
CN102219811B CN102219811B (zh) 2013-07-03

Family

ID=44776538

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201110093276 Active CN102219811B (zh) 2011-04-14 2011-04-14 Ca-4衍生物、其制法及其医药用途

Country Status (1)

Country Link
CN (1) CN102219811B (it)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288605A (zh) * 2013-06-06 2013-09-11 陕西师范大学 考布他丁的合成方法
CN103421057A (zh) * 2013-08-14 2013-12-04 合肥医工医药有限公司 康普瑞汀氨基糖缀合物、其制法及其医药用途
CN104817519A (zh) * 2015-05-11 2015-08-05 中国药科大学 一类ca-4的衍生物、其制法及其医药用途
CN106727629A (zh) * 2016-12-16 2017-05-31 中国药科大学 一种来源考布他汀a‑4衍生物的抗肿瘤机制研究
CN115403483A (zh) * 2021-07-02 2022-11-29 河南省儿童医院郑州儿童医院 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用
CN115887687A (zh) * 2022-11-23 2023-04-04 广东省科学院动物研究所 一种透明质酸(ha)-ca-4偶联物及其合成方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005682A1 (en) * 1992-08-31 1994-03-17 Francesca Pelizzoni Combretastatin derivatives with antitumoral activity and process for the preparation thereof
CN101591369A (zh) * 2008-05-30 2009-12-02 徐云根 N-糖基-3-芳基丙烯酰胺衍生物、其制法及其医药用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005682A1 (en) * 1992-08-31 1994-03-17 Francesca Pelizzoni Combretastatin derivatives with antitumoral activity and process for the preparation thereof
CN101591369A (zh) * 2008-05-30 2009-12-02 徐云根 N-糖基-3-芳基丙烯酰胺衍生物、其制法及其医药用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BROWN R. T. 等: "Synthesis of Water-soluble Sugar Derivatives of Combretastatin A-4", 《JOURNAL OF THE CHEMICAL SOCIETY. PERKIN TRANSACTIONS. I》 *
PETTIT, GEORGE R.等: "Antineoplastic agents. 322. Synthesis of combretastatin A-4 prodrugs", 《ANTI-CANCER DRUG DESIGN》 *
曲峰,等: "氢化可的松氨基糖衍生物的合成", 《有机化学》 *
李林鲜,等: "风车子抑素A4及其衍生物的研究进展", 《国际药学研究杂志》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288605A (zh) * 2013-06-06 2013-09-11 陕西师范大学 考布他丁的合成方法
CN103288605B (zh) * 2013-06-06 2015-04-08 陕西师范大学 考布他丁的合成方法
CN103421057A (zh) * 2013-08-14 2013-12-04 合肥医工医药有限公司 康普瑞汀氨基糖缀合物、其制法及其医药用途
CN103421057B (zh) * 2013-08-14 2016-03-30 合肥医工医药有限公司 康普瑞汀氨基糖缀合物、其制法及其医药用途
CN104817519A (zh) * 2015-05-11 2015-08-05 中国药科大学 一类ca-4的衍生物、其制法及其医药用途
CN104817519B (zh) * 2015-05-11 2016-11-16 中国药科大学 一类ca-4的衍生物、其制法及其医药用途
CN106727629A (zh) * 2016-12-16 2017-05-31 中国药科大学 一种来源考布他汀a‑4衍生物的抗肿瘤机制研究
CN115403483A (zh) * 2021-07-02 2022-11-29 河南省儿童医院郑州儿童医院 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用
CN115403483B (zh) * 2021-07-02 2024-01-26 河南省儿童医院郑州儿童医院 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用
CN115887687A (zh) * 2022-11-23 2023-04-04 广东省科学院动物研究所 一种透明质酸(ha)-ca-4偶联物及其合成方法和应用

Also Published As

Publication number Publication date
CN102219811B (zh) 2013-07-03

Similar Documents

Publication Publication Date Title
CN102219811B (zh) Ca-4衍生物、其制法及其医药用途
CN107148417B (zh) 苯并氮杂*磺酰胺化合物
CN110291065A (zh) 一种新的异二氢吲哚衍生物、其药物组合物及应用
CN104080455A (zh) 某些化学实体、组合物及方法
CN104053442A (zh) 某些化学实体、组合物及方法
JP2014525443A (ja) キヌレニン−3−モノオキシゲナーゼインヒビター、医薬組成物、およびこれらの使用方法
TWI706951B (zh) 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法
CN103421061A (zh) 来那度胺衍生物、其制法及其医药用途
CN103044395B (zh) 含有地氯雷他定结构的氨基酸类衍生物、其制备方法和用途
JP6855636B2 (ja) イミダゾリジン化合物
CN101624376B (zh) 取代酰肼类化合物及其应用
CN113784963A (zh) 用作ret激酶抑制剂的化合物及其应用
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN115417788A (zh) 一种抗炎化合物及其制备方法和用途
CN103421057B (zh) 康普瑞汀氨基糖缀合物、其制法及其医药用途
CN108299420A (zh) 作为选择性雌激素受体下调剂的五环类化合物及其应用
CN103748060B (zh) 1,3-二氧代茚衍生物、其药学上可接受的盐或光学异构体,其制备方法以及包含其作为抗病毒活性成分的药物组合物
KR102394934B1 (ko) Akt 억제제로서의 염 형태 및 이의 결정 형태
CN110294742B (zh) 并环类ask1抑制剂及其应用
CN101591364B (zh) 氨基糖衍生物、其制法及其医药用途
CN104586842B (zh) 一种抗癌活性吲哚衍生物、合成方法及其用途
CN101928323B (zh) 3,23,28位修饰的23-羟基白桦酸类衍生物、其制备方法、制剂及用途
CN104098524B (zh) 1-间甲氧基苯甲酰基-3-苯基-1,4-二氢-1,2,4,5-四嗪及制备和应用
CN110092789B (zh) 一种吲哚并[2,3-b]咔唑衍生物及其应用
Ishimoto et al. Convergent and streamlined synthesis of 6-etherified imidazo [1, 2-b] pyridazine-2-amine derivatives possessing VEGFR-2 kinase inhibitory activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24

Co-patentee after: Hefei Medical and Pharmaceutical Co., Ltd.

Patentee after: China Pharmaceutical University

Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24

Co-patentee before: Hefei Yigong Medicine Co., Ltd.

Patentee before: China Pharmaceutical University

CP01 Change in the name or title of a patent holder